Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Laboratory Corp of America Holdings, Medical Devices Deals, 2011 to YTD 2017 13
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deal Details 18
Asset Purchase 18
LabCorp Acquires High-Complexity Genomic Lab From Covance 18
LabCorp To Acquire MuirLab Business From John Muir Health 19
Sequenom Acquires Molecular Diagnostic Application Patents From Helicos BioSciences For US$1.3 Million 20
Gamma-Dynacare Medical To Acquire Quebec Operations Of Lifelabs 21
Gamma-Dynacare Medical Acquires Medical Labs Division Of Warnex 22
Venture Financing 23
Orig3n Raises USD20 Million in Venture Financing 23
Sera Prognostics Raises USD40 Million in Series C Financing 25
Orig3N Raises USD12.5 Million in Series A Financing 26
Orig3N Raises Funds through Venture Financing 28
Advanced Animal Diagnostics Raises USD15 Million in Series C Venture Financing 29
Flatiron Health Raises US$130 Million In Series B Financing 30
Private Equity 31
Chicago Growth Partners Acquires Caprion Proteomics For US$29 Million 31
Partnerships 32
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 32
Laboratory Corp Enters into Partnership with Capital Health 33
Emulate Enters into Agreement with Covance 34
Sequenom Enters into Agreement with University of Colorado Denver 35
Motif Bio Enters into Agreement with Covance 36
Sequenom Enters into Agreement with University Medical Center Hamburg 37
Sequenom Enters into Agreement with Seoul National University Hospital 38
Sequenom enters into an Agreement with University of California 39
Covance Enters into Co-Development Agreement with Sihuan Pharma 40
Covance Enters into Co-Development Agreement with Novartis Institutes for BioMedical Research 41
Covance Enters into Research Agreement with Frenova Renal Research 42
Gamma-Dynacare Medical Labs Enters Into Agreement With OSR Medical 43
Covance And Pathoquest Enter Into Agreement For Sequencing-Based Biosafety Assessments 44
Covance And Royal Liverpool and Broadgreen University Hospitals Enter Into Agreement To Offer Clinical Trials 45
GNS Healthcare Enters Into Co-Development Agreement With Covance 46
Bayer HealthCare Enters Into Agreement With Covance 47
Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 48
Covance Enters Into Research Agreement With Institute for Systems Biology For Tumor Biology 49
Ingenuity Systems Enters Into Research Collaboration With Covance Genomics 50
Takeda Enters Into Co-Development Agreement With Covance 51
LabCorp Enters Into Agreement With On-Q-ity 52
Licensing Agreements 53
LabCorp Enters into Licensing Agreement with Transgenomic 53
New England Biolabs Enters Into Licensing Agreement With Sequenom 54
Equity Offering 55
Sequenom Completes Public Offering Of Common Stock For US$62 Million 55
Debt Offering 57
LabCorp Raises USD500 Million in Public Offering of 3.2% Notes Due 2022 57
LabCorp Raises USD1 Billion in Public Offering of 3.6% Notes Due 2025 59
LabCorp Raises USD900 Million in Public Offering of 4.7% Notes Due 2045 61
LabCorp Raises USD500 Million in Public Offering of 2.625% Notes Due 2020 63
Covance Completes Private Placement Of Notes Due 2025 For US$95 Million 65
Covance Completes Private Placement Of Notes Due 2020 For US$50 Million 66
Covance Completes Private Placement Of Notes Due 2023 For US$90 Million 67
Covance Completes Private Placement Of Notes Due 2018 For US$15 Million 68
LabCorp Completes Public Offering Of Notes Due 2023 For US$300 Million 69
LabCorp Completes Public Offering Of Notes Due 2018 For US$400 Million 71
Sequenom Completes Private Placement Of Notes Due 2017 For US$130 Million 73
LabCorp Completes Public Offering Of Senior Notes Due 2017 For US$500 Million 74
LabCorp Completes Public Offering Of Senior Notes Due 2022 For US$500 Million 76
Asset Transactions 78
LabCorp Acquires High-Complexity Genomic Lab From Covance 78
Marken Acquires European Kit Building Operation Facility From LabCorp 79
Acquisition 80
LabCorp Acquires Chiltern International for USD1.2 Billion 80
Chiltern International Acquires Integrated Development Associates 82
LabCorp May Acquire Pharmaceutical Product Development 83
LabCorp Acquires Covance for USD6.1 Billion 84
BioLegend Acquires Covance Antibody Services from Covance 86
Agena Bioscience Completes Acquisition of Sequenom Bioscience for USD31.8 Million 87
Covance Acquires Medaxial 88
Gamma-Dynacare Medical Labs Acquires Lab Bio-Medic From Persistence Capital Partners 89
Gamma-Dynacare Medical Labs Acquires Controlling Interest In Impact Genetics 90
Gamma-Dynacare Medical Laboratories Acquires MedAxio Insurance Medical Services 91
LabCorp Completes Acquisition Of Medtox Scientific For US$241 Million 92
Smithers Viscient Services Completes Acquisition Of Environmental Sciences From Covance 94
LabCorp Completes Acquisition Of Orchid Cellmark For US$85 Million 95
Covance Acquires Trac Microbiology, Microbiology And Chemistry Laboratory 98
Lab Corporation Of America To Acquire Clearstone Central Labs 99
Pathology Holdings Acquires Central Coast Clinical Labs 100
Laboratory Corp of America Holdings – Key Competitors 101
Laboratory Corp of America Holdings – Key Employees 102
Laboratory Corp of America Holdings – Locations And Subsidiaries 103
Head Office 103
Other Locations & Subsidiaries 103
Recent Developments 108
Strategy And Business Planning 108
Apr 21, 2017: Covance to Expand Large-Molecule Development Capabilities in the UK 108
Financial Announcements 109
Oct 25, 2017: LabCorp Announces Record Third Quarter Results and Increases 2017 Guidance 109
Jul 26, 2017: LabCorp Announces Record Results in the Second Quarter of 2017 and Increases 2017 Guidance 111
Apr 25, 2017: Laboratory Corporation of America Holdings Announces 2017 First Quarter Results and Updates 2017 Guidance 114
Feb 16, 2017: Laboratory Corporation of America Holdings Announces Record 2016 Fourth Quarter and Full Year Results and Provides 2017 Guidance 116
Oct 26, 2016: Laboratory Corporation of America Holdings Announces 2016 Third Quarter Results and Updates 2016 Guidance 119
Jul 27, 2016: Laboratory Corporation of America Holdings Announces 2016 Second Quarter Results and Raises 2016 Guidance 121
Apr 25, 2016: Laboratory Corporation of America Holdings Announces 2016 First Quarter Results and Raises 2016 Guidance 123
Feb 18, 2016: Laboratory Corporation of America Holdings Announces 2015 Fourth Quarter and Full Year Results and Provides 2016 Guidance 125
Corporate Communications 128
Aug 24, 2017: LabCorp Names Nationally Recognized Health-Policy Expert Dr. Brian Caveney As Enterprise-Wide Chief Medical Officer 128
Jul 18, 2017: LabCorp’s William Hanlon Appointed to Governing Committee of the National Evaluation System for health Technology Coordinating Center 129
Mar 29, 2017: LabCorp Promotes Executive Gary Huff to CEO of LabCorp Diagnostics, One of the Company’s Two Primary Business Segments 130
Sep 20, 2016: LabCorp Names Veteran Biopharma Executive John Ratliff CEO of Covance Drug Development 131
Apr 11, 2016: LabCorp Hires Jonathan Zung as Group President of Clinical Development and Commercialization Services for Covance Drug Development 132
Jan 27, 2016: LabCorp and Cheeriodicals Spread Cheer to UNC Children’s 133
Legal and Regulatory 134
Dec 11, 2017: LabCorp Supports American Clinical Laboratory Association Lawsuit on PAMA Final Rule 134
Jun 15, 2017: Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation 135
Product News 136
Nov 16, 2017: Cority Enhances Clinical Testing Solution with LabCorp Interface 136
Appendix 137
Methodology 137
About GlobalData 137
Contact Us 137
Disclaimer 137
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Laboratory Corp of America Holdings, Deals By Therapy Area, 2011 to YTD 2017 11
Laboratory Corp of America Holdings, Medical Devices Deals, 2011 to YTD 2017 13
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
LabCorp Acquires High-Complexity Genomic Lab From Covance 18
LabCorp To Acquire MuirLab Business From John Muir Health 19
Sequenom Acquires Molecular Diagnostic Application Patents From Helicos BioSciences For US$1.3 Million 20
Gamma-Dynacare Medical To Acquire Quebec Operations Of Lifelabs 21
Gamma-Dynacare Medical Acquires Medical Labs Division Of Warnex 22
Orig3n Raises USD20 Million in Venture Financing 23
Sera Prognostics Raises USD40 Million in Series C Financing 25
Orig3N Raises USD12.5 Million in Series A Financing 26
Orig3N Raises Funds through Venture Financing 28
Advanced Animal Diagnostics Raises USD15 Million in Series C Venture Financing 29
Flatiron Health Raises US$130 Million In Series B Financing 30
Chicago Growth Partners Acquires Caprion Proteomics For US$29 Million 31
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 32
Laboratory Corp Enters into Partnership with Capital Health 33
Emulate Enters into Agreement with Covance 34
Sequenom Enters into Agreement with University of Colorado Denver 35
Motif Bio Enters into Agreement with Covance 36
Sequenom Enters into Agreement with University Medical Center Hamburg 37
Sequenom Enters into Agreement with Seoul National University Hospital 38
Sequenom enters into an Agreement with University of California 39
Covance Enters into Co-Development Agreement with Sihuan Pharma 40
Covance Enters into Co-Development Agreement with Novartis Institutes for BioMedical Research 41
Covance Enters into Research Agreement with Frenova Renal Research 42
Gamma-Dynacare Medical Labs Enters Into Agreement With OSR Medical 43
Covance And Pathoquest Enter Into Agreement For Sequencing-Based Biosafety Assessments 44
Covance And Royal Liverpool and Broadgreen University Hospitals Enter Into Agreement To Offer Clinical Trials 45
GNS Healthcare Enters Into Co-Development Agreement With Covance 46
Bayer HealthCare Enters Into Agreement With Covance 47
Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 48
Covance Enters Into Research Agreement With Institute for Systems Biology For Tumor Biology 49
Ingenuity Systems Enters Into Research Collaboration With Covance Genomics 50
Takeda Enters Into Co-Development Agreement With Covance 51
LabCorp Enters Into Agreement With On-Q-ity 52
LabCorp Enters into Licensing Agreement with Transgenomic 53
New England Biolabs Enters Into Licensing Agreement With Sequenom 54
Sequenom Completes Public Offering Of Common Stock For US$62 Million 55
LabCorp Raises USD500 Million in Public Offering of 3.2% Notes Due 2022 57
LabCorp Raises USD1 Billion in Public Offering of 3.6% Notes Due 2025 59
LabCorp Raises USD900 Million in Public Offering of 4.7% Notes Due 2045 61
LabCorp Raises USD500 Million in Public Offering of 2.625% Notes Due 2020 63
Covance Completes Private Placement Of Notes Due 2025 For US$95 Million 65
Covance Completes Private Placement Of Notes Due 2020 For US$50 Million 66
Covance Completes Private Placement Of Notes Due 2023 For US$90 Million 67
Covance Completes Private Placement Of Notes Due 2018 For US$15 Million 68
LabCorp Completes Public Offering Of Notes Due 2023 For US$300 Million 69
LabCorp Completes Public Offering Of Notes Due 2018 For US$400 Million 71
Sequenom Completes Private Placement Of Notes Due 2017 For US$130 Million 73
LabCorp Completes Public Offering Of Senior Notes Due 2017 For US$500 Million 74
LabCorp Completes Public Offering Of Senior Notes Due 2022 For US$500 Million 76
LabCorp Acquires High-Complexity Genomic Lab From Covance 78
Marken Acquires European Kit Building Operation Facility From LabCorp 79
LabCorp Acquires Chiltern International for USD1.2 Billion 80
Chiltern International Acquires Integrated Development Associates 82
LabCorp May Acquire Pharmaceutical Product Development 83
LabCorp Acquires Covance for USD6.1 Billion 84
BioLegend Acquires Covance Antibody Services from Covance 86
Agena Bioscience Completes Acquisition of Sequenom Bioscience for USD31.8 Million 87
Covance Acquires Medaxial 88
Gamma-Dynacare Medical Labs Acquires Lab Bio-Medic From Persistence Capital Partners 89
Gamma-Dynacare Medical Labs Acquires Controlling Interest In Impact Genetics 90
Gamma-Dynacare Medical Laboratories Acquires MedAxio Insurance Medical Services 91
LabCorp Completes Acquisition Of Medtox Scientific For US$241 Million 92
Smithers Viscient Services Completes Acquisition Of Environmental Sciences From Covance 94
LabCorp Completes Acquisition Of Orchid Cellmark For US$85 Million 95
Covance Acquires Trac Microbiology, Microbiology And Chemistry Laboratory 98
Lab Corporation Of America To Acquire Clearstone Central Labs 99
Pathology Holdings Acquires Central Coast Clinical Labs 100
Laboratory Corp of America Holdings, Key Competitors 101
Laboratory Corp of America Holdings, Key Employees 102
Laboratory Corp of America Holdings, Other Locations 103
Laboratory Corp of America Holdings, Subsidiaries 104
